Product Description
Panitumumab is a type of targeted cancer drug called a monoclonal antibody. It’s also known by its brand name, Vectibix. You might have it as a treatment for bowel cancer that has spread to other areas of the body (advanced). Panitumumab works by blocking signals that tell cancer cells to divide and grow. It attaches to a specific protein called epidermal growth factor receptor (EGFR) found on the surface of some cancer cells. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/panitumumab)
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, Korea, Mexico, Netherlands, Poland, Portugal, Romania, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
Active Clinical Trial Count: 29
Highest Development Phases
Phase 3: Colorectal Cancer|Sarcoma
Phase 2: Adenocarcinoma|Liver Cancer
Phase 1: Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2071240009 | P3 |
Not yet recruiting |
Colorectal Cancer |
2030-11-27 |
|
| 20210081 | P3 |
Unknown Status |
Colorectal Cancer |
2030-11-20 |
|
| FIRE-8 / AIO-KRK/YMO-0519 | P2 |
Active, not recruiting |
Colorectal Cancer |
2029-05-20 |
|
| CodeBreaK 301 | P3 |
Recruiting |
Colorectal Cancer |
2027-09-28 |